Skip to main content
Contact Us
Subscribe
E-Edition
69°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Immunome, Inc.
< Previous
1
2
Next >
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity
May 23, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports First Quarter 2023 Financial Results
May 05, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results
March 16, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present at 13th Annual World ADC London Conference
March 09, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board
February 08, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
January 06, 2023
From
Immunome, Inc.
Via
Business Wire
Tickers
ABBV
IMNM
Immunome Reports Third Quarter 2022 Financial Results
November 14, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 09, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer
August 23, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports Second Quarter 2022 Financial Results
August 05, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome’s COVID-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants* in the US, BA.4/5 and BA.2.12.1
July 06, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19
June 09, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present at the Jefferies Healthcare Conference
June 02, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38
May 23, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant
May 19, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports First Quarter 2022 Financial Results
May 12, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome’s Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in In Vitro Live Virus Testing
February 08, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19
January 10, 2022
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Participate in Fireside Chat Hosted by Cantor Fitzgerald
December 07, 2021
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant
December 01, 2021
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
November 29, 2021
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Reports Third Quarter 2021 Financial Results
November 15, 2021
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present at the Stifel Healthcare Conference
November 09, 2021
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis
October 20, 2021
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present at the Cantor Global Healthcare Conference
September 22, 2021
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 15, 2021
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing
September 07, 2021
From
Immunome, Inc.
Via
Business Wire
Tickers
IMNM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.